Navigating 6 Analyst Ratings For Zymeworks
Throughout the last three months, 6 analysts have evaluated Zymeworks (NASDAQ:ZYME), offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 2 | 3 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 1 | 0 | 0 |
| 2M Ago | 1 | 1 | 0 | 0 | 0 |
| 3M Ago | 0 | 1 | 1 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $12.0, a high estimate of $16.00, and a low estimate of $10.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 1.64%.
Breaking Down Analyst Ratings: A Detailed Examination
A comprehensive examination of how financial experts perceive Zymeworks is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Robert Burns | HC Wainwright & Co. | Maintains | Neutral | $10.00 | $10.00 |
| Robert Burns | HC Wainwright & Co. | Maintains | Neutral | $10.00 | - |
| Yigal Nochomovitz | Citigroup | Lowers | Buy | $16.00 | $17.00 |
| Derek Archila | Wells Fargo | Lowers | Overweight | $12.00 | $14.00 |
| Derek Archila | Wells Fargo | Raises | Overweight | $14.00 | $12.00 |
| Robert Burns | HC Wainwright & Co. | Raises | Neutral | $10.00 | $8.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Zymeworks. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Zymeworks compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Zymeworks's stock. This comparison reveals trends in analysts' expectations over time.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Zymeworks's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Zymeworks analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
All You Need to Know About Zymeworks
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
A Deep Dive into Zymeworks's Financials
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Zymeworks's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2024, the company experienced a revenue decline of approximately -71.81%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Zymeworks's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -315.58% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Zymeworks's ROE stands out, surpassing industry averages. With an impressive ROE of -7.01%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Zymeworks's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -5.58% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Zymeworks's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.06.
Analyst Ratings: What Are They?
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.